XTL Biopharmaceuticals Ltd.

Annual Report • Nov 24, 2021

Restatement of previously issued consolidated financial statements for Nine Months Ended September 30, 2020 false

��� �� �� ������������� ��"�	2 380
X T L BIOPHARMACEUTICALS LTD
Corporation no: 520039470	4313
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	24/11/2021
	www.isa.gov.il			www.tase.co.il				Reference:	2021-02-170832	Time of broadcast: 17:53 17:53

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onRestatement of previously issued consolidated financial statements for Nine Months Ended September 30, 2020

EDGAR2_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 19/10/2021
Address: HaCharoshet st 5 , Ra'anana 43656   Israel , Tel: 09-9557080 , Fax: 09-9519708
E-mail address: ir@xtlbio.com   Company site: www.xtlbio.com
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Name of the Signatory: Kntor Ronen Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company:
Address: abba hillel 12 , ramat gan 5250606 Telephone: 03-6133371 Facsimile: 03-6133372 E-mail: rkantor@dtkgc.com 1